1. Introduction
===============

A number of secondary metabolites with potential pharmacological activities such as cytotoxic, antiviral, anti-inflammatory, and insecticidal effects were discovered from marine organisms \[[@b1-marinedrugs-09-01477]\]. Marine diterpenoids of the class briarane have been investigated with great interest owing to their novel structures and interesting bioactivities \[[@b2-marinedrugs-09-01477]--[@b5-marinedrugs-09-01477]\]. The gorgonian of the genus *Junceella* grown in the tropical and subtropical waters of Indo-West Pacific regions are well known as a source of highly oxidized briarane-type diterpenoids with a γ-lactone moiety \[[@b6-marinedrugs-09-01477]--[@b9-marinedrugs-09-01477]\]. In continuation of our study on the chemistry and biological activities of briarane diterpenoids \[[@b10-marinedrugs-09-01477]--[@b16-marinedrugs-09-01477]\], we investigated the Taiwanese gorgonian *J. fragilis*. A chemical investigation of the acetone extract has yielded four new 8-hydroxybriarane diterpenoids, designated as frajunolides L--O (**1**--**4**). In this paper, we report the isolation, structural elucidation, and anti-inflammatory activity as tested by superoxide anion generation and elastase release by human neutrophil in response to fMLP/CB, of these compounds.

2. Results and Discussion
=========================

Compound **1** was deduced to have the molecular formula C~28~H~38~O~11~ with ten degrees of unsaturation from high-resolution ESI mass spectrometry. The IR absorptions were observed at 3439, 1768 and 1735 cm^−1^ suggesting the presence of hydroxyl, γ-lactone and ester groups, respectively. The ^1^H-, ^13^C-NMR and DEPT spectroscopic data ([Table 1](#t1-marinedrugs-09-01477){ref-type="table"}) revealed that compound **1** possessed four acetyl groups (*δ*~H~ 1.94, 1.98, 2.13, and 2.21), two tertiary methyl protons (*δ*~H~ 1.15, Me-15; *δ*~H~ 2.03, Me-16), a doublet methyl (*δ*~H~ 1.15, *d*, *J* = 6.9 Hz, Me-19), five oxygenated methine protons (*δ*~H~ 4.94, *t*, *J* = 3.3 Hz, H-2; *δ*~H~ 5.28, *d*, *J* = 9.6 Hz, H-7; *δ*~H~ 5.62, *d*, *J* = 5.1 Hz, H-9; *δ*~H~ 5.32, *m*, H-12; 4.77, br *s*, H-14), a trisubstituted olefinic group (*δ*~H~ 5.58, *d*, *J* = 9.6 Hz, H-6; *δ*~C~ 120.0, C-6; *δ*~C~ 145.2, C-5), an oxygenated quaternary carbon (*δ*~C~ 82.6, C-8), an exocyclic double bond (*δ*~H~ 5.34, 5.30, H~2~-20; *δ*~C~ 118.3, C-20; 146.3, C-11), two methine carbons (*δ*~C~ 40.6, C-10; *δ*~C~ 43.2, C-17), three methylene carbons (*δ*~C~ 30.8, C-3; *δ*~C~ 29.0, C-4; *δ*~C~ 33.5, C-13), along with a γ-lactone carbonyl carbon (*δ*~C~ 175.9, C-18). The proton and carbon assignments of **1** were completely established by using 1D- and 2D NMR experiments, including ^1^H-^1^H COSY, HSQC, and HMBC ([Figure 1](#f1-marinedrugs-09-01477){ref-type="fig"}). The ^1^H-^1^H COSY spectrum exhibited four sets of correlations (H-2/H-3/H-4, H-6/H-7, H-9/H-10, and H-12/H-13/H-14). The HMBC correlations of Me-15 (*δ*~H~ 1.15, *s*)/C-1 (*δ*~C~ 47.0), C-2 (*δ*~C~ 74.2), C-10 (*δ*~C~ 40.6), C-14 (*δ*~C~ 73.6); Me-16 (*δ*~H~ 2.03, *s*)/C-4 (*δ*~C~ 29.0), C-5 (*δ*~C~ 145.2), C-6 (*δ*~C~ 120.0); Me-19 (*δ*~H~ 1.15, *d*, *J* = 6.9 Hz)/C-8 (*δ*~C~ 82.6), C-18 (*δ*~C~ 175.9); H-9 (*δ*~H~ 5.62, *d*, *J* = 5.1 Hz)/C-8, C-7 (*δ*~C~ 78.0); H-10 (*δ*~H~ 3.57, *d*, *J* = 5.1 Hz)/C-1, C-2, C-11 (*δ*~C~ 146.3), C-12 (*δ*~C~ 71.5); H~2~-20 (*δ*~H~ 5.34, s; 5.30, s)/C-11, C-12; H-13 (*δ*~H~ 1.95, *m*; 2.20, *m*)/C-14, C-1 established the connectivities from C-1 to C-20 unambiguously, and revealed that compound **1** belongs to 8-hydroxybriarane diterpenoids with a γ-lactone ring \[[@b11-marinedrugs-09-01477]\]. The four acetate groups of **1** were assigned at C-2, C-9, C-12, and C-14 positions by the HMBC correlations between the acetate carbonyl carbons (*δ*~C~ 170.4 × 2, 170.3, and 168.9) and four oxygenated methine protons (*δ*~H~ 4.94, H-2; *δ*~H~ 5.62, H-9; *δ*~H~ 5.32, H-12; 4.77, H-14). Thus the planar structure of **1** was completely established.

Our results showed that the planar structure of compound **1** is the same as frajunolide A, but differing in the ^1^H- and ^13^C NMR data of the methylenecyclohexane ring, especially at C-12 and C-20 positions \[[@b10-marinedrugs-09-01477]\]. The ^13^C NMR chemical shift of C-12 (*δ*~C~ 71.5) was shifted downfield in comparison with frajunolide A (*δ*~C~ 67.3), suggesting that the relative stereochemistry of H-12 was *α*-orientation \[[@b11-marinedrugs-09-01477]\]. The relative configuration of **1** was determined by NOESY correlations ([Figure 1](#f1-marinedrugs-09-01477){ref-type="fig"}) and MM2 minimized energy calculated molecular modeling, and comparison with other naturally occurring briarane diterpenoids \[[@b2-marinedrugs-09-01477]--[@b5-marinedrugs-09-01477]\]. Briarane-type diterpenoids were reported to have the Me-15 in the *β*-orientation and H-10 in the *α*-orientation. In the NOESY of **1**, H-10 showed correlations with H-2, H-9, H-12, suggesting that these protons are located on the *α*-face. In addition, the correlation between H-9 and Me-19 indicated that Me-19 is *α*-oriented too. However, correlation of H-17/H-7 suggested that H-7 and H-17 are on the *β*-face. Moreover, NOESY correlation of H-14/Me-15 suggested that 14-acetoxy group is located on the *α*-face. The *Z*-configuration at C-5 was elucidated by the observation of NOESY correlation between H-6 and Me-16. On the basis of the above interpretation, the structure of compound **1** was elucidated. The name frajunolide L was given.

Compound **2** had the molecular formula C~28~H~38~O~11~, the same as that of **1**, as determined by HRESIMS, suggesting that the structure of **2** was similar to **1**. The IR spectrum of **2** also displayed strong absorptions at 3429, 1776 and 1735 cm^−1^ indicating that compound **2** contained hydroxyl and carbonyl groups of five-membered γ-lactone ring and ester groups. Both ^1^H- and ^13^C NMR spectroscopic data ([Table 1](#t1-marinedrugs-09-01477){ref-type="table"}) of **2** were found to be similar to those of **1**. These signals include four acetyl group (*δ*~H~ 1.92, 2.01, 2.07, and 2.16), two tertiary methyl protons (*δ*~H~ 0.99, Me-15; *δ*~H~ 1.99, Me-16), a methyl doublet (*δ*~H~ 1.17, *d*, *J* = 6.8 Hz, Me-19), and a methine quartet (*δ*~H~ 1.15, *q*, *J* = 7.2 Hz). However, 1D- and 2D-spectroscopic data of **2** revealed that the exocyclic double bond (C-11/C-20) in **1** shifted to C-12 (*δ*~C~ 127.6)/C-11 (*δ*~C~ 134.2) and an acetate group was found to locate at C-20 (*δ*~C~ 68.7). The gross structure of **2** was further deduced from the ^1^H-^1^H COSY, HMQC, HMBC correlations ([Figure 2](#f2-marinedrugs-09-01477){ref-type="fig"}). The relative configuration of **2** was determined by NOESY correlations ([Figure 2](#f2-marinedrugs-09-01477){ref-type="fig"}) and application of MM2 molecular modeling together with comparing the NMR spectra of **2** with those of **1**. The NOESY correlations of H-10/H-2, H-9, and H-9/Me-19 suggested that the configurations of H-2, H-9, H-10, and Me-19 were in *α*-orientation while correlations of H-7/H-6, H-17, and H-14/Me-15 agreed with *β*-disposition of H-7, H-14, Me-15 and H-17.

The HRESI mass spectrum of **3** gave a *quasi*-molecular ion peak at *m/z* 589.2266 \[M + Na\]^+^, indicative of a molecular formula C~28~H~38~ClO~12~ (calc. for *m/z* 589.2261), consistent with 10 degrees of unsaturation. The presence of a chloride was evident from the fragment \[M + Na\]^+^ at *m/z* 589 and the isotope fragment \[M + Na + 2\]^+^ at *m/z* 591 in ESIMS, with the typical ratio of relative intensity (3:1) in the mass spectrum. In the infrared spectrum, strong absorption bands were found at 3436, 1735 and 1780 cm^−1^ characteristic for hydroxyl, ester carbonyl (acetyl) and five-membered γ-lactone ring, suggesting a briarane-type diterpenoid similar to compounds **1** and **2**. It was found that the ^1^H- and ^13^C NMR spectra of **3** in CDCl~3~ showed mostly broad peaks and in some cases, certain peaks were not observed. In order to mark more optimum signals of the NMR spectra, compound **3** was dissolved in pyridine-*d*~5~. The ^1^H- and ^13^C NMR data ([Table 1](#t1-marinedrugs-09-01477){ref-type="table"}) of **3** revealed the presence of four acetate groups (*δ*~H~ 1.99, 2.11, and 2.30 × 2; *δ*~C~ 172.5, 171.1 × 2, 170.3, 22.2, 21.9, 21.8, and 21.5), an exocyclic double bond (*δ*~H~ 5.83, 5.42, H~2~-16; *δ*~C~ 144.0, C-5; 125.5, C-16) and a γ-lactone carbonyl carbon (*δ*~C~ 176.4, C-19). Judging from the molecular formula and NMR data of **3**, six degrees of unsaturation were counted for, indicating that compound **3** contained a tetracyclic system including an exocyclic epoxide (*δ*~H~ 2.84, *d*, *J* = 4.0 Hz; 2.59, br s, H~2~-20; *δ*~C~ 58.2, C-11; 52.6, C-20). The HMBC correlations ([Figure 3](#f3-marinedrugs-09-01477){ref-type="fig"}) between H-2 (*δ*~H~ 6.68, *d*, *J* = 8.5 Hz), H-4 (*δ*~H~ 5.90, *d*, *J* = 10.5 Hz), H-9 (*δ*~H~ 6.30, *s*), and H-14 (*δ*~H~ 5.25, *s*) with one of ester carbonyl carbons, respectively, revealed that four acetyl groups were connected to the C-2, C-4, C-9, and C-14 positions. By interpretation of the NMR spectroscopic data, the planar structure of compound **3** was elucidated. The relative configuration of **3** was determined by NOESY ([Figure 3](#f3-marinedrugs-09-01477){ref-type="fig"}) and detailed comparison with known compounds \[[@b10-marinedrugs-09-01477]\]. The chemical shift of C-11 (*δ*~C~ 58.2) and C-20 (*δ*~C~ 52.6), and the NOESY correlations between H~2~-20 and Me-15 agreed with *β*-face of H~2~-20, 11*R*-configuration regarding the exocyclic epoxide, and chair conformation of the cyclohexane ring. Furthermore, NOESY correlations of H-10/H-2, H-4/H-2 and H-10/H-9 suggested that H-2, H-4 and H-9 were located on the same face and could be assigned as α.

Compound **4** showed a pair of *quasi*-molecular ion peaks at *m/z* 607 and 609 \[M + H\]^+^ with a ratio of 3:1 in the ESIMS, indicating the presence of a chlorine atom. Moreover, a molecular formula C~28~H~37~ClO~11~ was established by HRESIMS and confirmed by ^1^H- and ^13^C NMR spectroscopic analysis ([Table 1](#t1-marinedrugs-09-01477){ref-type="table"}). The IR absorption bands at 3467, 1780 and 1739 cm^−1^ indicated that **4** contained hydroxyl, γ-lactone, and ester carbonyl functionalities similar to **1**--**3**. Detailed inspection of ^1^H- and ^13^C NMR spectroscopic data revealed the presence of the key structural feature of a 8-hydroxybriarane diterpenoid with two exocyclic double bonds. The locations of the two exocyclic double bonds were confirmed by the HMBC experiment ([Figure 4](#f4-marinedrugs-09-01477){ref-type="fig"}), which showed correlations of H~2~-16 (*δ*~H~ 4.92, *s*; 5.49, *s*)/C-4 (*δ*~C~ 33.4), C-5 (*δ*~C~ 144.9), and C-6 (*δ*~C~ 56.2), and H~2~-20 (*δ*~H~ 4.92, *s*; 5.19, *s*)/C-10 (*δ*~C~ 44.6), C-11 (*δ*~C~ 147.0), and C-12 (*δ*~C~ 38.6), respectively. In addition, the oxygenated methine proton H-2 (*δ*~H~ 6.62, *d*, *J* = 8.0 Hz), H-9 (*δ*~H~ 6.28,), H-13 (*δ*~H~ 5.72, *ddd*, *J* = 12.0, 5.2, 3.2 Hz), and H-14 (*δ*~H~ 5.66, *s*) showed HMBC correlations with the acetate carbonyl carbons (*δ*~C~ 171.8, 170.9, 170.8, 170.3). Furthermore, detailed analysis of 2D NMR spectroscopic data (^1^H-^1^H COSY and HMBC) established the planar structure of **4**. The configuration of compound **4** was determined on the basis of NOESY correlations ([Figure 4](#f4-marinedrugs-09-01477){ref-type="fig"}). The NOESY correlations of Me-15 (*δ*~H~ 1.27, *s*)/H-14 and H-13/H-14 implied that H-13 and H-14 are on the *β*-face while correlations of H-2/H-10, H-10/H-9, H-9/Me-19, H-17/H-7 and H-6/H-7 confirmed that the configuration of these protons are identical to those of compound **3**.

General pharmacological study of the anti-inflammatory activities of compounds **1**--**4** were evaluated by measuring superoxide anion generation and elastase release by human neutrophils in response to fMet-Leu-Phe (fMLP)/Cytochalasin B (CB) \[[@b17-marinedrugs-09-01477]\]. The results are illustrated in [Table 2](#t2-marinedrugs-09-01477){ref-type="table"}. Compounds **1** and **4** showed mild inhibitory effects on both superoxide anion generation and elastase release at 10 μg/mL. It is notable that compound **3** exhibited selective but modest inhibition of elastase release *in vitro*.

3. Experimental Section
=======================

3.1. General Experimental Procedures
------------------------------------

Optical rotations were recorded on a JASCO DIP-1000 polarimeter. IR spectra were measured on a Hitachi T-2001 spectrophotometer. The ^1^H-^13^C NMR, COSY, HMQC, HMBC, and NOESY spectra were recorded on a Bruker AV-400 or a AV-500 spectrometer, using TMS as internal standard. The chemical shifts are given in *δ* (ppm) and coupling constants (*J*) in Hz. HRESIMS were run on a JEOL JMS-HX 110 mass spectrometer. Silica gel 60 (Merck) was utilized for column chromatography, and precoated silica gel plates (Merck, Kieselgel 60 F-254, 1 mm) were used in preparative TLC. Sephadex LH-20 (Amersham Pharmacia Biotech AB, Sweden) was used for separation and purification of compounds. LiChrospher Si 60 (5 μm, 250-10, Merck) and LiChrospher 100 RP-18e (5 μm, 250-10, Merck) were used in NP-HPLC and RP-HPLC (Hitachi), respectively.

3.2. Animal Material
--------------------

The gorgonian *Junceella fragilis* Ridley (Ellisellidae) was collected in Tai-Tong County, Taiwan, by scuba diving at a depth of 15 meters, in February 2006. The fresh gorgonian was immediately frozen after collection and kept at −20 °C until processing. A voucher specimen (WSG-5) was deposited in the School of Pharmacy, College of Medicine, National Taiwan University, Taipei.

3.3. Extraction and Isolation
-----------------------------

The gorgonian *J. fragilis* (wet, 2.5 kg) was minced and extracted with acetone (3 × 5 L) at room temperature and the acetone extract was concentrated under vacuum. The crude extract (20 g) was partitioned between EtOAc and H~2~O (1:1). The EtOAc-soluble portion (15 g) was subjected to column chromatography using silica gel and eluted with a gradient of *n*-hexane/EtOAc (10:1 to 0:1) to obtain thirteen fractions (Fr.1\~13). Fraction 6 (202 mg) was subjected to RP-HPLC using MeOH/H~2~O (60:40) to give **1** (3.9 mg) and **2** (1.8 mg). Fraction 9 (874 mg) was separated on silica gel column and eluted with gradient *n*-hexane/EtOAc to give seven fractions (Fr. 9-1\~6). Fr. 9-4 (157 mg) was purified by RP-HPLC, using solvent mixture of MeOH and H~2~O (65:35) to yield **4** (8.2 mg). Fr. 9-6 (211 mg) was separated on RP-HPLC using MeOH/H~2~O (60:40) to furnish **3** (4.5 mg).

Frajunolide L (**1**): colorless amorphous gum; \[α\]^24^ ~D~ +6.0 (*c* 0.2, CH~2~Cl~2~); IR *ν*~max~ 3439, 2922, 2749, 1768, 1735, 1370, 1248, 1221, 1040 cm^−1;\ 1^H NMR data (400 MHz, CDCl~3~), see [Table 1](#t1-marinedrugs-09-01477){ref-type="table"}; ^13^C NMR data (100 MHz, CDCl~3~), see [Table 2](#t2-marinedrugs-09-01477){ref-type="table"}; ESIMS *m/z* 573 \[M + Na\]^+^; HRESIMS *m/z* 573.2313 \[M + Na\]^+^ (calcd for C~28~H~38~O~11~Na, 573.2312).

Frajunolide M (**2**): colorless amorphous powder; \[α\]^24^ ~D~ +8.0 (*c* 0.2, CH~2~Cl~2~); IR *ν*~max~ 3447, 2923, 2853, 1773, 1735, 1645, 1375, 1240, 1223, 1041 cm^−1;\ 1^H NMR data (400 MHz, CDCl~3~), see [Table 1](#t1-marinedrugs-09-01477){ref-type="table"}; ^13^C NMR data (100 MHz, CDCl~3~), see [Table 2](#t2-marinedrugs-09-01477){ref-type="table"}; ESIMS *m/z* 573 \[M + Na\]^+^; HRESIMS *m/z* 573.2315 \[M + Na\]^+^ (calcd for C~28~H~38~O~11~Na, 573.2312).

Frajunolide N (**3**): colorless amorphous powder; \[α\]^24^ ~D~ +18.0 (*c* 0.1, CH~2~Cl~2~); IR *ν*~max~ 3436, 2933, 1780, 1735, 1376, 1255, 1235, 1212, 1044, 1017 cm^−1;\ 1^H NMR data (400 MHz, pyridine-*d*~5~), see [Table 1](#t1-marinedrugs-09-01477){ref-type="table"}; ^13^C NMR data (100 MHz, pyridine-*d*~5~), see [Table 2](#t2-marinedrugs-09-01477){ref-type="table"}; ESIMS *m/z* 589 \[M + Na\]^+^, 591 \[M + Na + 2\]^+^; HRESIMS *m/z* 589.2266 \[M + Na\]^+^ (calcd for C~28~H~38~ClO~12~Na, 589.2261).

Frajunolide O (**4**): colorless amorphous gum; \[α\]^24^ ~D~ +6.7 (*c* 0.7, CH~2~Cl~2~); IR *ν*~max~ 3467, 2927, 1780, 1739, 1368, 1250, 1223, 1041 cm^−1;\ 1^H NMR data (400 MHz, pyridine-*d*~5~), see [Table 1](#t1-marinedrugs-09-01477){ref-type="table"}; ^13^C NMR data (100 MHz, pyridine-*d*~5~), see [Table 2](#t2-marinedrugs-09-01477){ref-type="table"}; ESIMS *m/z* 607 \[M\]^+^; HRESIMS *m/z* 607.1925 \[M + Na\]^+^ (calcd for C~28~H~37~ClO~11~Na, 607.1922), 609.1892 \[M + Na + 2\]^+^.

3.4. Human Neutrophils Superoxide Generation and Elastase Release
-----------------------------------------------------------------

Human neutrophils were obtained by means of dextran sedimentation and Ficoll centrifugation. The assay of O~2~ ^•−^ generation was based on the SOD-inhibitable reduction of ferricytochrome *c*. Degranulation of azurophilic granules was determined by elastase release as described previously \[[@b16-marinedrugs-09-01477]\]. The elastase release experiments were performed using MeO-Suc-Ala-Ala-Pro-Val-*p*-nitroanilide as the elastase substrate. The fMet-Leu-Phe (fMLP), activated by Cytochalasin B (CB), was used as a stimulant. Genistein was used as a standard compound.

4. Conclusion
=============

Chemical investigation of the Taiwanese gorgonian *Junceella fragilis* has resulted in the isolation of four new briarane diterpenoids, frajunolides L--O (**1**--**4**). Among them, compounds **1**, **3** and **4** exhibited mild or selective anti-inflammatory activity.
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==================

[Supplementary data](#SD1){ref-type="supplementary-material"} associated with this article can be found in the online version.
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###### 

NMR spectroscopic data for compounds **1**--**4**.

         **1**[b](#tfn2-marinedrugs-09-01477){ref-type="table-fn"}   **2**[b](#tfn2-marinedrugs-09-01477){ref-type="table-fn"}   **3**[c](#tfn3-marinedrugs-09-01477){ref-type="table-fn"}   **4**[c](#tfn3-marinedrugs-09-01477){ref-type="table-fn"}                                                                       
  ------ ----------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ----------------------- -------------- ---------------------------- --------------
  1                                                                  47.0, C                                                                                                                 45.7, C                                                                             48.9, C                                     48.3, C
  2      4.94, t (3.3)                                               74.2, CH                                                    5.01, m                                                     75.0, CH                                                    6.68, d (8.5)           73.2, CH       6.62, d (8.0)                74.8, CH
  3      2.16, m                                                     30.8, CH~2~                                                 2.54, m                                                     33.3, CH~2~                                                 3.58, dd (16.0, 10.5)   37.3, CH~2~    2.88, m                      29.3, CH~2~
         1.72, m                                                                                                                 1.61, m                                                                                                                 2.03, dd (16.0, 8.5)                   1.70, m                      
  4      2.58, m                                                     29.0, CH~2~                                                 1.95, m                                                     29.7, CH~2~                                                 5.90, d (10.5)          77.6, CH       2.52, m                      33.4, CH~2~
         2.08, m                                                                                                                                                                                                                                                                                                             
  5                                                                  145.2, C                                                                                                                146.1, C                                                                            144.0, C                                    144.9, C
  6      5.58, d (9.6)                                               120.0, CH                                                   5.41, d (9.2)                                               117.7, CH                                                   5.42, d (3.5)           54.2, CH       5.21, d (3.2)                56.2, CH
  7      5.28, d (9.6)                                               78.0, CH                                                    5.32, d (9.2)                                               79.1, CH                                                    4.94, d (3.5)           85.3, CH       4.92, m                      84.9, CH
  8                                                                  82.6, C                                                                                                                 82.5, C                                                                             82.7, C                                     82.1, C
  9      5.62, d (5.1)                                               72.6, CH                                                    5.74, s                                                     71.4, CH                                                    6.30, s                 72.6, CH       6.28, s                      79.3, CH
  10     3.57, d (5.1)                                               40.6, CH                                                    3.07, s                                                     39.9, CH                                                    3.62, s                 42.4, CH       3.82, s                      44.6, CH
  11                                                                 146.3, C                                                                                                                134.2, C                                                                            58.2, C                                     147.0, C
  12     5.32, m                                                     71.5, CH                                                    5.85 br, s                                                  127.6, CH                                                   2.27, m                 31.6, CH~2~    2.63, t (12.4)               38.6, CH~2~
                                                                                                                                                                                                                                                         1.28, m                                2.49, m                      
  13     2.20, m                                                     33.5, CH~2~                                                 2.28, m                                                     28.1, CH~2~                                                 1.94, m                 25.5, CH~2~    5.27, ddd (3.2, 5.2, 12.0)   70.1, CH
         1.95, m                                                                                                                 2.11, m                                                                                                                                                                                     
  14     4.77 br, s                                                  73.6, CH                                                    4.75 br, s                                                  73.7, CH                                                    5.25, s                 75.2, CH       5.66, s                      73.8, CH
  15     1.15, s                                                     15.4, CH~3~                                                 0.99, s                                                     16.2, CH~3~                                                 1.31, s                 15.2, CH~3~    1.27, s                      14.4, CH~3~
  16     2.03, s                                                     27.0, CH~3~                                                 1.99, s                                                     29.0, CH~3~                                                 5.83, s                 125.5, CH~2~   4.92, s                      118.3, CH~2~
                                                                                                                                                                                                                                                         5.42, s                                5.49, s                      
  17     2.54, q (6.9)                                               43.2, CH                                                    2.45, q (7.2)                                               44.7, CH                                                    3.44, q (7.0)           51.8, CH       3.41, q (7.6)                51.4, CH
  18                                                                 175.9, C                                                                                                                174.7, C                                                                            176.4, C                                    175.8, C
  19     1.15, d (6.9)                                               6.7, CH~3~                                                  1.17, d (6.8)                                               8.7, CH~3~                                                  1.41, d (7.0)           7.3, CH~3~     1.26, d (7.6)                6.7, CH~3~
  20     5.34, s                                                     118.3, CH~2~                                                4.67, d (12.0)                                              68.7, CH~2~                                                 2.84, d (4.0)           52.6, CH~2~    4.92, s                      113.1, C
         5.30, s                                                                                                                 5.02, d (12.0)                                                                                                          2.59 br, s                             5.19, s                      
  OAc    2.21, s                                                     170.4, C                                                    2.16, s                                                     169.9, C                                                    2.30, s                 172.5, C       2.28, s                      171.8, C
         2.13, s                                                     170.4, C                                                    2.07, s                                                     169.7, C                                                    2.30, s                 171.1, C       2.09, s                      170.9, C
         1.98, s                                                     170.3, C                                                    2.01, s                                                     169.3, C                                                    2.11, s                 171.1, C       2.07, s                      170.8, C
         1.94, s                                                     168.9, C                                                    1.92, s                                                     168.4, C                                                    1.99, s                 170.3, C       1.99, s                      170.3, C
                                                                     21.7, CH~3~                                                                                                             23.1, CH~3~                                                                         22.2, CH~3~                                 21.9, CH~3~
                                                                     21.2, CH~3~                                                                                                             22.9, CH~3~                                                                         21.9, CH~3~                                 21.1, CH~3~
                                                                     21.2, CH~3~                                                                                                             22.8, CH~3~                                                                         21.8, CH~3~                                 21.0, CH~3~
                                                                     21.1, CH~3~                                                                                                             22.7, CH~3~                                                                         21.5, CH~3~                                 20.9, CH~3~
  8-OH                                                                                                                                                                                                                                                                                          8.05 br, s                   

Data were recorded at 400 and/or 500 MHz in CDCl~3~;

In CDCl~3~;

In pyridine-*d*~5~;

Data recorded at 100 and/or 125 MHz and were assigned by DEPT, COSY, HSQC, and HMBC experiments.

###### 

Effects of compounds on superoxide anion generation and elastase release by human neutrophils in response to fMet-Leu-Phe (fMLP)/Cytochalasin B (CB).

  Compounds   Superoxide anion Inh % [a](#tfn5-marinedrugs-09-01477){ref-type="table-fn"}   Elastase release Inh % [a](#tfn5-marinedrugs-09-01477){ref-type="table-fn"}
  ----------- ----------------------------------------------------------------------------- -----------------------------------------------------------------------------
  **1**       18.7 ± 2.6 [\*\*](#tfn7-marinedrugs-09-01477){ref-type="table-fn"}            16.2 ± 0.7 [\*\*\*](#tfn8-marinedrugs-09-01477){ref-type="table-fn"}
  **2**       2.0 ± 2.3                                                                     13.3 ± 3.1 [\*](#tfn6-marinedrugs-09-01477){ref-type="table-fn"}
  **3**       0.6 ± 1.5                                                                     22.3 ± 7.7
  **4**       8.3 ± 3.6                                                                     17.2 ± 6.7 [\*](#tfn6-marinedrugs-09-01477){ref-type="table-fn"}
  Genistein   65.0 ± 5.7                                                                    51.6 ± 5.9

Percentage of inhibition Inh % at 10 μg/mL concentration. Results are presented as mean ± S.E.M. (*n* = 3).

*P* \< 0.05,

*P* \< 0.01,

*P* \< 0.001 compared with the control value.
